6108 — New Ray Medicine International Holding Cashflow Statement
0.000.00%
- HK$41.13m
- HK$6.17m
- HK$130.37m
Annual cashflow statement for New Ray Medicine International Holding, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.61 | -80.3 | -22.3 | -32.1 | -19.9 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 5.52 | 54.1 | 4.94 | 12.3 | 11.4 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -69.9 | 15.7 | -37.8 | 8.16 | -51.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -58.4 | -0.318 | -45.4 | -4.77 | -54.1 |
| Capital Expenditures | -0.059 | -8.7 | -0.044 | -0.622 | -0.31 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 131 | 10.3 | -5.97 | -30.3 | 8.31 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 131 | 1.62 | -6.01 | -30.9 | 8.01 |
| Financing Cash Flow Items | -0.28 | -0.177 | -0.032 | -0.102 | -0.256 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 10.1 | -12.5 | -1.01 | -1.58 | 6.11 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 84.4 | 4.26 | -50.5 | -39.7 | -34.8 |